Milind Dattatraya Sindkhedkar

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 9.4

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Chikalthana Aurangabad, IN (2008)
Maharashtra, IN (2010 - 2014)
Pune, IN (2012 - 2024)

Company Filing History:

Years Active: 2008-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435066 - Substituted tricyclic compounds (2025-10-07),

2. 12391695 - PRMT5 inhibitors (2025-08-19),

3. 11952380 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2024-04-09),

4. 11459330 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2022-10-04),

5. 9000175 - Bicyclic GPR119 modulators (2015-04-07),

6. 8729269 - Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy (2014-05-20),

7. 8217058 - Substituted piperidino phenyloxazolidinones (2012-07-10),

8. 8097594 - Macrolides and ketolides having antimicrobial activity (2012-01-17),

9. 7687627 - Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy (2010-03-30),

10. 7405228 - Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites (2008-07-29),

Title: Milind Dattatraya Sindkhedkar: Innovator in Pharmaceutical Research

Introduction

Milind Dattatraya Sindkhedkar is a notable inventor based in Pune, India, with a remarkable portfolio of eight patents. His contributions to the field of pharmaceutical research have significantly advanced the understanding and treatment of various diseases.

Latest Patents

Among his latest inventions are novel substituted bicyclic heterocyclic compounds designed as PRMT5 inhibitors. These compound formulations encompass pharmaceutically acceptable salts and provide pharmaceutical compositions aimed at treating diseases, disorders, or conditions linked to the overexpression of the PRMT5 enzyme. Furthermore, his inventions outline methods for effectively addressing such overexpression-related health issues.

Career Highlights

Milind has built his career at prominent pharmaceutical companies, including Wockhardt Limited and Lupin, Inc. Through his work at these organizations, he has been instrumental in developing innovative solutions that showcase his expertise and dedication to the field.

Collaborations

Throughout his professional journey, Milind has collaborated with notable individuals such as Mahesh Vithalbhai Patel and Prasad Keshav Deshpande. These partnerships have fostered an environment of creativity and advancement in pharmaceutical research.

Conclusion

Milind Dattatraya Sindkhedkar exemplifies the spirit of innovation in the pharmaceutical industry. With his ongoing research and patent contributions, he continues to pave the way for new therapeutic options, making a lasting impact on healthcare and disease treatment.

This text is generated by artificial intelligence and may not be accurate.